Patricia Philco Lima1*, Aydeé Cristina Ramírez Laura1, Marlene Isabel Suxo Tejada2, Ángela María Clara Alanes Fernandez M.D2, Aida Virginia Choque Churqui MD3, Omar Erick Paye Huanca3, Luz Jaqueline Farah Bravo4, Nina Rosa Yaksic Feraude4 and Carlos Ascaso Terren5
Background: The identification of the metabolic syndrome is essential for a timely diagnosis and to avoid type 2 diabetes, the objective was to determine the validity of the FINDRISC test and glycated hemoglobin for risk screening for diabetes mellitus in a high-altitude resident population (3600 m.a.s.l.) city of La Paz-Bolivia 2018.
Methods: Analytical study of diagnostic tests, the gold test was the definition of metabolic syndrome according to the criteria of the Harmonization Consensus, compared with the FINDRISC test and glycated hemoglobin. People with an age greater than or equal to 18, who agreed to participate, were included. Pregnant women, people with cancer or thyroid disease were excluded.
Results: 400 people were included. There were 358 women (89.5%) and 42 men (10.5%) with age of 48.38 ± 14.1 years old. The prevalence of metabolic syndrome was 46.75%. The area under the curve, sensitivity, specificity, positive predictive value and positive likelihood ratio of FINDRISC with cut-off point 10 were 0.7073(CI 95% 0.66-0.75), 74.33%(CI 95% 67.34-80.30), 67.14%(CI 95% 60.33- 73.31), 66.51%(CI 95% 59.62-72.78) and 2.26(CI95% 1.83-2.79) respectively. With FINDRISC's (cut-off point 10) and HbA1c (cut-off point 5.7%) together, were 0.8025 (CI 95% 0.74-0.84), 88.1%(CI 95% 80.82-92.96), 72.41%(CI 95% 63.21-80.11), 77.62%(CI 95% 69.74-83.98) and 3.19 (CI 95% 2.36-4.32) respectively.
Conclusion: The FINDRISC test is a good metabolic syndrome screening test, with a cut point of 10; this is synergized with 5.7% for HbA1c in a high-altitude resident population (3600 m.a.s.l.).
